AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Trial Identifier:	D7230C00001
Sponsor:	AstraZeneca
Start Date:	December 2023
Primary Completion Date:	August 2026
Study Completion Date:	August 2026
Condition:	Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
AU	Melbourne, AU, 3000
AU	Nedlands, AU, 6009
CA, ON	Hamilton, ON, CA, L8V 5C2
CA, ON	Ottawa, ON, CA, K1H 8L6
CA, Québec	Montreal, Québec, CA, H4A 3J1
CN	Beijing, CN, 100044
CN	Changsha, CN, 410013
CN	Guangzhou, CN, 510060
CN	Shenyang, CN, 110134
DE	Essen, DE, 45147
DE	Freiburg, DE, 79106
DE	Hamburg, DE, 20246
DE	Lübeck, DE, 23538
DE	Nürnberg, DE, 90419
DE	Wuerzburg, DE, 97080
ES	Madrid, ES, 28041
ES	Madrid, ES, 28027
ES	Pamplona, ES, 31005
ES	Salamanca, ES, 37007
FR	Lille, FR, 59037
FR	Nantes, FR, 44000
JP	Kashiwa, JP, 277-8577
JP	Nagoya-shi, JP, 467-8602
JP	Yamagata-shi, JP, 990-9585
US, CA	Duarte, CA, US, 91010
US, CA	Irvine, CA, US, 92618
US, GA	Atlanta, GA, US, 30322
US, MA	Boston, MA, US, 02215
US, MI	Ann Arbor, MI, US, 48109
US, MO	Saint Louis, MO, US, 63110
US, NY	New York, NY, US, 10065
US, PA	Philadelphia, PA, US, 19104
US, VA	Fairfax, VA, US, 22031

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company